Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...

University of Virginia School of Medicine researchers have uncovered a possible way to prevent the dangerous hardening of skin and organs in people with systemic scleroderma, a rare autoimmune disease ...

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

MONTREAL, January 27, 2026--(BUSINESS WIRE)--Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, ...

Background Systemic sclerosis, also known as scleroderma, is a complex, multi-organ disease which causes substantial and progressive fibrosis of the skin and internal organs, including the heart and ...

Scleroderma is a rare autoimmune disease involving an overproduction of the protein collagen. Linear scleroderma usually begins as a streak of hardened, waxy, discolored skin on the forehead, an arm, ...

Scleroderma is an autoimmune condition that causes the skin to become tight and hard. This can change facial appearance, such as the mouth becoming smaller, and affect internal organs. With ...

Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and sometimes fatal illness stiffens and scars tissue in organs like the lungs, ...

Systemic sclerosis (SSc) or scleroderma is a rare, chronic, autoimmune disorder that hardens connective tissue and muscle in the body. As a result, this can generate complications associated with skin ...